SEARCH

SEARCH BY CITATION

Keywords:

  • FGF23;
  • FAMILIAL HYPOPHOSPHATEMIA;
  • FAM20C;
  • RAINE SYNDROME;
  • EXOME SEQUENCING

ABSTRACT

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

Fibroblast growth factor 23 (FGF23) plays a crucial role in renal phosphate regulation, exemplified by the causal role of PHEX and DMP1 mutations in X-linked hypophosphatemic rickets and autosomal recessive rickets type 1, respectively. Using whole exome sequencing we identified compound heterozygous mutations in family with sequence similarity 20, member C (FAM20C) in two siblings referred for hypophosphatemia and severe dental demineralization disease. FAM20C mutations were not found in other undiagnosed probands of a national Norwegian population of familial hypophosphatemia. Our results demonstrate that mutations in FAM20C provide a putative new mechanism in human subjects leading to dysregulated FGF23 levels, hypophosphatemia, hyperphosphaturia, dental anomalies, intracerebral calcifications and osteosclerosis of the long bones in the absence of rickets.


Introduction

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

Over the last decade, our understanding of human phosphate metabolism, including genes and mechanisms involved, has greatly increased. Of particular importance is the characterization of a bone-kidney signaling pathway that includes a new class of phosphate regulating molecules; i.e., the phosphatonins.[1] Fibroblast growth factor 23 (FGF23) has been recognized as a key phosphate regulating hormone in this pathway, inhibiting the renal reabsorption of phosphate through regulation of sodium-phosphate co-transporters in proximal tubule cells, and downregulating the 1-alpha-hydroxylase responsible for the conversion of 25-hydroxy vitamin D (25(OH)D) to 1,25-dihydroxyvitamin D (1,25(OH)2D).[2] The net effect is a reduction of body phosphate in response to increasing levels of serum phosphate, 1,25(OH)2D or parathyroid hormone (PTH).[3]

Elevated levels of FGF23 result in phosphaturia, hypophosphatemia, and low or inappropriately normal levels of 1,25(OH)2D as occurs in various monogenic renal wasting conditions such as X-linked hypophosphatemic rickets (XLH) caused by PHEX mutations,[4] autosomal dominant hypophosphatemic rickets (ADHR) caused by FGF23 mutations,[5] and autosomal recessive hypophosphatemic rickets (ARHR) type 1 caused by DMP1 mutations.[6] A recent work described a second form of ARHR, ARHR type 2, caused by ENPP1 mutations, associated with arterial calcification of infancy and elevated FGF23 levels.[7] The clinical spectrum of FGF23-dependent disorders and our understanding of their genetic basis is continuously expanding,[8, 9] allowing for increased insight into the pathophysiological mechanisms involved in hypophosphatemic conditions.

In this study, we investigated a family with an autosomal recessive pattern of hypophosphatemia, hyperphosphaturia, dental anomalies, intracerebral calcifications, and osteosclerosis of the long bones. Using whole-exome sequencing, we aimed to find the genetic explanation and assess the relationship of the findings to the serum levels of FGF23.

Patients and Methods

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

Subjects

The family was recruited from a national population-based cohort of familial hypophosphatemia in Norway and included two affected brothers (Fig. 1). A detailed description of their clinical history is given in the supplementary material (Clinical report). Written informed consent was obtained from all study participants. The study was approved by the Regional Committee for Medical and Health Research Ethics, Region West, Norway (REK number 2009/1140).

image

Figure 1. (A) Family pedigree. (B) Picture of the face and hands of sibling 1 and 2 and their unaffected father. Note the high forehead, flat, broad nasal bridge, hypotelorism, flat malar area, and short distal phalanges in the brothers, as compared to their father.

Download figure to PowerPoint

Biochemical parameters

Blood samples were collected after an overnight fast. Circulating levels of Ca, albumin, phosphate, and alkaline phosphatase (ALP) activity in serum were analyzed using the Modular P-system from Roche Diagnostics (Basel, Switzerland). PTH was measured with a two-site chemiluminescent enzyme-labeled immunometric assay for intact PTH (Immulite 2000; Siemens Healthcare Diagnostics, Deerfield, IL, USA). Measurement of 25(OH)D levels was performed using an in-house–developed liquid chromatography double mass spectrometry (LC-MS/MS) method.[10] A spot sample of urine collected at the time of blood sampling was analyzed for calcium, phosphorus, and creatinine. The maximal tubular reabsorption of phosphate per glomerular filtration rate (TmP/GFR) was calculated according to the algorithm based on the nomogram of Walton and Bijvoet.[11, 12] Plasma intact FGF23 was measured with the FGF23-ELISA kit (Kainos Laboratories, Japan), with a lower detection limit of 3 pg/mL and a intraassay coefficient of variation (CV) of 5.8%, and inter assay CV of 7.5%.

Genetic analysis

Genomic DNA was purified from blood using the QiaSymphony system (Qiagen, Hilden, Germany). Whole-genome single-nucleotide polymorphism (SNP) genotyping was performed with Genome-Wide Human SNP 6.0 array (Affymetrix, Santa Clara, CA, USA). Whole-exome capture using Roche-Nimblegen's SeqCap EZ Exome v2 and sequencing on the Illumina HiSeq was performed at the HudsonAlpha Institute for Biotechnology (Huntsville, AL, USA) to a median coverage of 154× according to the manufacturer's protocol.[13] The paired-end 100-nt reads were analyzed with CASAVA v1.8 (Illumina Inc., San Diego, CA, USA) followed by alignment with Burrows-Wheeler transformation.[14] PCR duplicates were removed with PICARD (http://picard.sourceforge.net) and the Genome analysis toolkit (GATK) was used for base quality recalibration.[15] SNPs and indels were called using the GATK unified genotyper using a minimum threshold of 8× sequencing depth and quality score ≥30. ANNOVAR[16] and in-house scripts were used for variant annotation.

Sanger sequencing of FAM20C

Exon 3 and 4 of family with sequence similarity 20, member C (FAM20C), including the intron-exon boundaries, were sequenced in all five members of the family.

In short, DNA targets were first amplified by PCR (list of primers available upon request) using the AmpliTaq Gold DNA polymerase system (Applied Biosystems, Life Biosystems, Carlsbad, CA, USA). PCR amplicons were purified with 2 µL of ExoSapIT. Using the Big Dye Terminator, chemistry sequencing was performed on the 3730 DNA analyzer (Applied Biosystems) and analyzed using the SeqScape software (Applied Biosystems).

All exons and intron/exon boundaries of FAM20C were sequenced in an additional five Norwegian subjects with familial hypophosphatemia, for which mutational analysis of the PHEX, DMP1, FGF23, ENPP1, and Klotho genes had not revealed the underlying genetic cause. In addition, we sequenced FAM20C in five PHEX-negative subjects with hypophosphatemia and variable degrees of osteosclerosis, from the Yale Center for XLH.

Results

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

Clinical studies

We investigated a family in which the affected individuals displayed a pattern of autosomal recessive hypophosphatemia and hyperphosphaturia (Fig. 1, Table 1), in whom tooth decay was evident by approximately 18 months of age, and in whom osteosclerosis rather than rickets was later found in radiographs of long bones. After puberty, the degree of renal phosphate wasting gradually diminished such that by 18 to 20 years of age, the affected brothers had circulating phosphate levels in the lower normal range and urine phosphate excretion in the higher normal range (Fig. 2, Table S1). In addition, the subjects displayed ectopic calcifications in the brain, as well as mild facial and acral dysmorphic features (see Supplementary Fig. S1 and the Supplementary Material/Clinical report for a detailed clinical description). Previous genetic studies had revealed no chromosomal disorders or mutations in the PHEX, FGF23, or DMP1. The father, the mother, and the half-brother had normal serum and urine phosphate levels (Table 1), normal teeth, and no dysmorphic features.

Table 1. Biochemical Parameters at Inclusion
ParameterNormal rangeUnitSibling 1 (18 years old)Sibling 2 (16 years old)Mother (48 years old)Father (46 years old)
  1. s = serum; ALP = alkaline phosphatase activity; iPTH = intact parathyroid hormone; FGF23 = fibroblast growth factor 23; TmP/GFR = tubular maximum reabsorption of phosphate/glomerular filtration rate.

  2. a

    Reference values for s-phosphorus are age- and sex-dependent: male and female 1–17 years: 1.2–1.8 mmol/L; female >17 years: 0.85–1.65 mmol/L; male 18–49 years: 0.75–1.65 mmol/L; male >49: 0.75–1.35 mmol/L.

  3. b

    Reference values for s-ALP are age-dependent: <18 years: <400 U/L; >18 years: 35–105 U/L.

  4. c

    Conversion factor: pmol/L × 9.497 = pg/mL.

  5. d

    Reference value from the laboratory in which our samples were measured.[13]

s-PhosphateAge dependentammol/L0.880.991.021.35
s-Calcium2.2–2.55mmol/L2.442.382.262.35
s-Magnesium0.71–0.94mmol/L0.980.960.930.86
s-ALPAge dependentbU/L1754436049
s-iPTH1.3–6.8cpmol/L5.91211.45.2
s-1,25 (OH)2 vitamin D50–150nmol/LNA196NA146
FGF23<50dpg/mL90894940
TmP/GFR>0.85mmol/L0.710.80.891.14
image

Figure 2. Development of (A) s-phosphate levels and (B) TmP/GFR with age for the two affected siblings. The symbol represents sibling 1 and the symbol × represents sibling 2. The broken lines represent the upper and lower limits of the reference interval.

Download figure to PowerPoint

Genetic studies

Whole-genome SNP genotyping in all family members did not reveal any large region of shared homozygosity between the two affected siblings and we therefore decided to perform whole-exome sequencing on sibling 1. Median exome coverage was 154 ×. We found a total of 18,036 variants in the exome, out of which 8560 were within coding regions (excluding synonymous variants). After filtering against an in-house database of variants found in other whole-exome sequenced Norwegian samples and the 1000 Genomes database (http://www.1000genomes.org) (>0.5% allele frequency), we were left with 207 very rare variants in sibling 1 (Table 2). Using a recessive disease model, only 12 genes remained. Next, using the whole-genome genotyping SNP data we excluded eight of the genes not shared two-identical-by-descent by the affected siblings (for autosomes) and two gene-variants on the X-chromosome carried identically by the non-affected half-brother. Of the two remaining candidate genes; FAM20C and ANKRD36B, only the FAM20C c.C803T/c.C915A mutations could be verified in the proband. The putative homozygous ANKRD36B c.G1627A/p.D543N mutation showed only a borderline quality score and suboptimal mapping quality in the exome sequencing data and could not be validated by Sanger Sequencing. We consider this an erroneous call.

Table 2. Variant Filtration of Exome Sequencing Data From Individual 1 Compared With Whole-Genome Genotyping Data From the Two Affected Siblings, Their Parents, and Their Half-Brother Revealed Two Novel Compound Heterozygous Mutations in the FAM20C Gene as the Most Likely Cause of the Disease in the Family
FilterCount
  1. a

    Segregation analysis was performed using whole-genome genotyping data from the two affected siblings, their parents, and their half-brother. Eight genes on the autosomes were excluded (not shared 2-IBD by the affected brother), and two gene variants located on the X-chromosome could be excluded as they reside on the identical haplotype carried by the unaffected half-brother.

  2. b

    Only the FAM20C c.C803T/c.C915A mutations were confirmed in both affected patients. The putative homozygous ANKRD36B c.G1627A/p.D543N mutation had low mapping quality and borderline quality score and could not be validated by Sanger Sequencing. We consider this an erroneous call.

Exomic variants18,036
Excluding synonymous8,560
Not in in-house database240
Not in 1000 Genomes (0.5% MAF)207
Putative recessive12 genes
In regions segregating with disease in the familya2 genes
Validated by Sanger sequencing in the familyb1 gene

Thus, the FAM20C gene appeared to be the only likely candidate gene, and on sequencing we identified compound heterozygous mutations in the FAM20C gene in both affected subjects. There was a missense mutation in exon 3 (c.803 C > T, p.T268M) inherited from the mother, located in the ATP-binding P-loop, and a nonsense mutation in exon 4 (c.915 C > A, p.Y305X) inherited from the father (Fig. 3A). The latter is predicted to cause a premature truncation of the protein, and is unlikely to lead to a viable protein. In addition, the missense mutation in exon 3 was found in heterozygous state in the half-brother. None of the two mutations were found in 192 healthy Norwegian blood donors.

image

Figure 3. (A) Overview of the FAM20C gene and mutations identified so far.[23][25][31][32] Green brackets signify survivors and red brackets signify lethal cases. In the gene/protein model, blue color represents the signal peptide at amino acid position 1–26, whereas green color represents the kinase domain (Pfam 06702; DUF 1193) at amino acid position 353–573. In our family we found a missense mutation in exon 3 (c.803 C > T, p.T268M) inherited from the mother, affecting the ATP-binding P-loop, and a nonsense mutation in exon 4 (c.915 C > A, p.Y305X) inherited from the father. (B) Scatter diagram of the FGF23 values in the presented family.

Download figure to PowerPoint

FGF23 analysis

We assessed FGF23 levels in the studied family members and found that the affected subjects had elevated FGF23 levels (Fig. 3B, Table 1). The unaffected mother and father had normal FGF23 levels. The half-brother was not available for FGF23 testing.

Discussion

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

Using whole-exome sequencing in a Norwegian family, we identified mutations in FAMC20 associated with autosomal recessive hypophosphatemia, suggesting that this condition may represent a third form of ARHR. Recent murine data supports the notion that inactivation of FAMC20 leads to hypophosphatemia.[17] Moreover, FGF23 levels were elevated in our affected family members, as well as in bone cells and serum of FAMC20 knockout mice,[17] indicating that our patients may suffer from a new monogenic form of FGF23-related hypophosphatemia and hyperphosphaturia. We screened DMP1- and PHEX-negative subjects from a national Norwegian population-based material of familial hypophosphatemia and selected U.S. patients with familial hypophosphatemia and osteosclerosis for FAM20C mutations, but were unable to identify other families. Hence, recessive FAM20C mutations do not appear to be a common cause of classical hypophosphatemia.

The affected family members had hypophosphatemia secondary to renal phosphate wasting and the hallmarks of an FGF23-mediated disorder; i.e., inappropriate normal levels of 1,25(OH)2D and PTH within or slightly above the normal range. Interestingly, the renal phosphate wasting decreased after puberty and at the age of 18 to 20 years, both brothers had normal circulating phosphate levels and no significant hyperphosphaturia. A similar pattern has been described in some families with ADHR,[18-20] and it has been speculated whether this phenomenon may be caused by adaptation to the increased levels or altered metabolism of FGF23 over time.[18-20] The FGF23 levels were significantly elevated in the two affected siblings,[21, 22] even after the renal phosphate wasting defect was gone. The mechanisms by which FAM20C mutations are linked to FGF23-mediated renal phosphate wasting and hypophosphatemia are at the moment unclear. FAM20C mutations have previously been associated with Raine syndrome, a rare disorder originally described as a lethal syndrome of microcephaly, hypoplastic nose, exophthalmos, gum hyperplasia, cleft palate, low-set ears, and osteosclerosis.[23-25] Recently, four cases of non-lethal Raine syndrome have been described, and of the three in which s-phosphate was measured, two had hypophosphatemia.[23, 25] We demonstrate for the first time that FAM20C mutations are also associated with nonlethal, monogenic, FGF23-dependent hypophosphatemia.

FAM20C is composed of 10 exons spanning 605 bp, and encodes the phosphorylation enzyme Golgi-enriched fraction casein kinase (GEF-CK). There is a short N-terminal signal peptide (amino acid position 1–22) and a highly conserved domain, the Pfam 06702 (DUF 1193) in the C-terminal end, at amino acid position 354–573. Within the Pfam-domain there are highly conserved residues necessary for the kinase activity, as well as a Greek key calcium binding domain, and an RDG (Arg-Gly-Asp) motif.[26] A recent publication suggests the SIBLING-proteins to be substrates for FAM20C27 and shows that osteopontin (OPN), DMP1 and matrix extracellular phosphoglycoprotein (MEPE) are phosphorylated by FAM20C in vitro.[27] Actually, the recently reported FAM20c knockout model shows a phenotype resembling the DMP1 knockout mouse phenotype. Moreover, in these mice, loss of FAM20c resulted in a significant downregulation of DMP1.[17] Dentin sialophosphoprotein (DSPP) is also included in the SIBLING protein family, and contain the S-x-E motif recognized by FAM20C.[28] The overlapping clinical features of dentinogenesis imperfecta type II[29] and Raine syndrome may suggest that DSPP may also be a substrate for FAM20C. Moreover, it has earlier been reported that a phosphorylation defect of osteopontin in Hyp-mice is due to defective activity of skeletal casein kinase activity in these mice.[30] Taken together, defective phosphorylation seems to be a mechanism that is involved in the pathways that generate FGF23-dependent hypophosphatemia.

When comparing the genetically characterized cases of Raine syndrome in literature, we found that the lethal cases had mutations that affected the highly conserved Pfam domain in the C-terminal part of FAMC20.[31, 32] In contrast, most of the surviving cases have had mutations in the N-terminal part of FAMC20 (see Fig. 3A).[23, 25] There is, however, one exception in which a mild phenotype was associated with the mutation c.1351 G > A that leads to the substitution of aspartic acid by asparagine at position 451 in the Pfam domain.[23] It is possible that the structural similarities between these two amino acids may explain why this mutation may be less damaging. Although one may speculate that FAM20C mutations affecting the C-terminal part of the GEF-CK may result in a more severe phenotype, a confirmation of this will have to await further studies.

In the family we report, a severe dental phenotype was associated with mutations in the FAM20C gene. Although the dental anomalies were of clinical and histological similarity to those in XLHR and ARHR type 1, both cases had dental anomalies starting at a very early age and affecting both deciduous and permanent teeth, rendering them both edentulous before the age of 18 years. Thus the dental phenotype appears to be more severe in FAM20C mutations than in most cases of XLH. Earlier surviving patients with Raine syndrome have also shown dental effects23,25 and, recently, two different groups have demonstrated that FAM20C knockout mice have significantly defective formation and mineralization of dentin, cementum, and enamel[17] or show an amelogenesis imperfecta (AI) phenotype.[33] In addition, the dental phenotype of our patients closely matched the findings in dentinogenesis imperfecta type II, a disorder caused by mutations in the putative FAMC20-encoded protein substrate DSPP.[29] Taken together, these findings suggest that phosphorylation of SIBLING proteins by FAM20C-encoded protein may be important for proper amelo- and dentinogenesis.

The FGF23-mediated hypophosphatemic disorders may be associated with a variety of skeletal affections. Typically, XLHR and ADHR are characterized by rickets and osteomalacia,[34] but adults with XLHR often demonstrate higher than average bone mineral density by dual-energy X-ray absorptiometry (DXA),[35] and radiographs may have a sclerotic appearance,[36] whereas patients with ARHR type 1 show osteosclerosis of the skull bones and rickets of the long bones.[37] The affected brothers of our family with FAM20C mutations had osteosclerosis of the long bones, but no rickets, a picture also observed earlier in the few surviving patients with Raine syndrome.[23, 25] In contrast, the mice in the FAM20C inactivation model were characterized by rickets and no osteosclerosis,[17] a discrepancy that may suggest species-specific differences in gene expression.[38]

The reported patients show intracerebral calcifications, especially in the periventricular white matter and basal ganglia, a feature in common with Raine syndrome patients.[23, 25, 31, 32, 39-48] Recently, Wang and colleagues[49] identified mutations in SLC20A2, encoding the type III sodium-dependent phosphate transporter 2 (PiT2), in families affected by idiopathic basal ganglia calcification. Ectopic calcification in other tissues, e.g., enthesopathies, is an important feature of the different hereditary hypophosphatemic disorders, including XLHR,[50] ARHR-I,[37] and ARHR-II.[51] The exact mechanism behind these ectopic calcifications needs to be studied further.[37] In the reported siblings, the intracerebral calcifications have remained stable during the last years.

An important characteristic of Raine syndrome, also found in the two brothers in this study, is dysmorphic features of the midface. A flat nasal bridge and a high arched or cleft palate, as well as dental involvement, have been described in most cases. Associations between FAM20C and both the canonical WNT and the transforming growth factor β (TGFβ) signaling pathways have been reported,[17, 52] both important in the development of the palate.[53] Taken together this may point to a role for FAM20C-encoded protein phosphorylation function in the embryonic development of structures in the head region.

In conclusion, we have identified the nonlethal variant of Raine syndrome as a new form of FGF23-related hypophosphatemia and hyperphosphaturia associated with FAMC20 mutations, and we propose this disease entity to be the third autosomal recessive form of hypophosphatemia. Additional clinical features of this hypophosphatemic disorder include a severe dental phenotype, intracerebral calcifications, osteosclerosis, as well as facial and acral dysmorphic features.

Acknowledgments

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

The family members are thanked for making this study possible, by being available for clinical examination and blood tests, as well as giving access to medical information. We also thank Ketil Mevold, MD at Nordland County Hospital, for the initial referral of the family and the staff at the Centre of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen Norway for technical support.

Authors' roles: SHR, HR, SJ, and RB designed the study; SHR, HR, AKF, TOC, and SJ collected the data; SHR, HR, PK, TOC, SJ, and RB contributed to data analysis and interpretation. The manuscript was drafted by SHR, HR, SJ, and RB. All authors contributed to the revision and approved the final version of the manuscript.

References

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information
  • 1
    Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118(12):38208.
  • 2
    Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U.S.A. 2001; 98(11):65005.
  • 3
    Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006; 17(5):130515.
  • 4
    Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, Lehrach H, Rowe PSN, Goulding JN, Summerfield T, Mountford R, Read AP, Popowska E, Pronicka E, Davies KE, O'Riordan JLH, Econs MJ, Nesbitt T, Drezner MK, Oudet C, Pannetier S, Hanauer A, Strom TM, Meindl A, Lorenz B, Cagnoli B, Mohnike KL, Murken J, Meitinger T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995; 11(2):1306.
  • 5
    ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26 3 345–8.
  • 6
    Bastepe M, Juppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord. 2008; 9(2):17180.
  • 7
    Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010; 86(2):26772.
  • 8
    Raeder H, Rafaelsen S, Bjerknes R. Monogenic phosphate balance disorders. In: Diamanti-Kandarakis E, editor. Contemporary aspects of endocrinology [Internet]. New York: InTech; [cited 2012 Dec 19]. Available from: http://www.intechopen com/books/contemporary-aspects-of-endocrinology/monogenic-phosphate-balance-disorders. 2011.
  • 9
    Bergwitz C, Juppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol. 2012; 728:4164.
  • 10
    Grimnes G, Almaas B, Eggen AE, Emaus N, Figenschau Y, Hopstock LA, Hutchinson MS, Methlie P, Mihailova A, Sneve M, Torjesen P, Wilsgaard T, Jorde R. Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed. Eur J Endocrinol. 2010; 163(2):33948.
  • 11
    Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975; 2(7929):30910.
  • 12
    Barth JH, Jones RG, Payne RB. Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram. Ann Clin Biochem. 2000; 37(Pt 1):7981.
  • 13
    Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, Aniebo IC, Bailey DM, Bancarz IR, Banerjee S, Barbour SG, Baybayan PA, Benoit VA, Benson KF, Bevis C, Black PJ, Boodhun A, Brennan JS, Bridgham JA, Brown RC, Brown AA, Buermann DH, Bundu AA, Burrows JC, Carter NP, Castillo N, Chiara ECM, Chang S, Neil-Cooley R, Crake NR, Dada OO, Diakoumakos KD, Dominguez-Fernandez B, Earnshaw DJ, Egbujor UC, Elmore DW, Etchin SS, Ewan MR, Fedurco M, Fraser LJ, Fuentes-Fajardo KV, Scott-Furey W, George D, Gietzen KJ, Goddard CP, Golda GS, Granieri PA, Green DE, Gustafson DL, Hansen NF, Harnish K, Haudenschild CD, Heyer NI, Hims MM, Ho JT, Horgan AM, Hoschler K, Hurwitz S, Ivanov DV, Johnson MQ, James T, Huw-Jones TA, Kang GD, Kerelska TH, Kersey AD, Khrebtukova I, Kindwall AP, Kingsbury Z, Kokko Gonzales PI, Kumar A, Laurent MA, Lawley CT, Lee SE, Lee X, Liao AK, Loch JA, Lok M, Luo S, Mammen RM, Martin JW, McCauley PG, McNitt P, Mehta P, Moon KW, Mullens JW, Newington T, Ning Z, Ling-Ng B, Novo SM, O'Neill MJ, Osborne MA, Osnowski A, Ostadan O, Paraschos LL, Pickering L, Pike AC, Pike AC, Chris Pinkard D, Pliskin DP, Podhasky J, Quijano VJ, Raczy C, Rae VH, Rawlings SR, Chiva Rodriguez A, Roe PM, Rogers J, Rogert Bacigalupo MC, Romanov N, Romieu A, Roth RK, Rourke NJ, Ruediger ST, Rusman E, Sanches Kuiper RM, Schenker MR, Seoane JM, Shaw RJ, Shiver MK, Short SW, Sizto NL, Sluis JP, Smith MA, Ernest Sohna Sohna J, Spence EJ, Stevens K, Sutton N, Szajkowski L, Tregidgo CL, Turcatti G, Vandevondele S, Verhovsky Y, Virk SM, Wakelin S, Walcott GC, Wang J, Worsley GJ, Yan J, Yau L, Zuerlein M, Rogers J, Mullikin JC, Hurles ME, McCooke NJ, West JS, Oaks FL, Lundberg PL, Klenerman D, Durbin R, Smith AJ. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008; 456(7218):539.
  • 14
    Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):175460.
  • 15
    McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297303.
  • 16
    Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164.
  • 17
    Wang X, Wang S, Li C, Gao T, Liu Y, Rangiani A, Sun Y, Hao J, George A, Lu Y, Groppe J, Yuan B, Feng JQ, Qin C. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet. 2012; 8(5):e1002708.
  • 18
    Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997; 82(2):67481.
  • 19
    Kruse K, Woelfel D, Strom TM. Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Hormone Res. 2001; 55(6):3058.
  • 20
    Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007; 22(4):5206.
  • 21
    Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008; 42(6):12359.
  • 22
    Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006; 91(6):205561.
  • 23
    Simpson MA, Scheuerle A, Hurst J, Patton MA, Stewart H, Crosby AH. Mutations in FAM20C also identified in non-lethal osteosclerotic bone dysplasia. Clin Genet. 2009; 75(3):2716.
  • 24
    Raine J, Winter RM, Davey A, Tucker SM. Unknown syndrome: microcephaly, hypoplastic nose, exophthalmos, gum hyperplasia, cleft palate, low set ears, and osteosclerosis. J Med Genet. 1989; 26(12):7868.
  • 25
    Fradin M, Stoetzel C, Muller J, Koob M, Christmann D, Debry C, Kohler M, Isnard M, Astruc D, Desprez P, Zorres C, Flori E, Dollfus H, Doray B. Osteosclerotic bone dysplasia in siblings with a Fam20C mutation. Clin Genet. 2011; 80(2):17783.
  • 26
    Hao J, Narayanan K, Muni T, Ramachandran A, George A. Dentin matrix protein 4, a novel secretory calcium-binding protein that modulates odontoblast differentiation. J Biol Chem. 2007; 282(21):1535765.
  • 27
    Tagliabracci VS, Engel JL, Wen J, Wiley SE, Worby CA, Kinch LN, Xiao J, Grishin NV, Dixon JE. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science. 2012; 336(6085):11503.
  • 28
    Kawasaki K, Suzuki T, Weiss KM. Genetic basis for the evolution of vertebrate mineralized tissue. Proc Natl Acad Sci U.S.A. 2004; 101(31):1135661.
  • 29
    Barron MJ, McDonnell ST, Mackie I, Dixon MJ. Hereditary dentine disorders: dentinogenesis imperfecta and dentine dysplasia. Orphanet J Rare Dis. 2008; 3:31.
  • 30
    Rifas L, Cheng S, Halstead LR, Gupta A, Hruska KA, Avioli LV. Skeletal casein kinase activity defect in the HYP mouse. Calcif Tissue Int. 1997; 61(3):25629.
  • 31
    Simpson MA, Hsu R, Keir LS, Hao J, Sivapalan G, Ernst LM, Zackai EH, Al-Gazali LI, Hulskamp G, Kingston HM, Prescott TE, Ion A, Patton MA, Murday V, George A, Crosby AH. Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. Am J Hum Genet. 2007; 81(5):90612.
  • 32
    Kochar GS, Choudhary A, Gadodia A, Gupta N, Simpson MA, Crosby AH, Kabra M. Raine syndrome: a clinical, radiographic and genetic investigation of a case from the Indian subcontinent. Clin Dysmorphol. 2010; 19(3):1536.
  • 33
    Vogel P, Hansen GM, Read RW, Vance RB, Thiel M, Liu J, Wronski TJ, Smith DD, Jeter-Jones S, Brommage R. Amelogenesis Imperfecta and Other Biomineralization Defects in Fam20a and Fam20c Null Mice. Vet Pathol. 2012; 49(6):9981017.
  • 34
    Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab. 2012; 30(1):19.
  • 35
    Reid IR, Murphy WA, Hardy DC, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. Am J Med. 1991; 90(1):639.
  • 36
    Marie PJ, Glorieux FH. Bone histomorphometry in asymptomatic adults with hereditary hypophosphatemic vitamin D-resistant osteomalacia. Metab Bone Dis Relat Res. 1982; 4(4):24953.
  • 37
    Makitie O, Pereira RC, Kaitila I, Turan S, Bastepe M, Laine T, Kroger H, Cole WG, Juppner H. Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation. J Bone Miner Res. 2010; 25(10):216574.
  • 38
    Harries LW, Brown JE, Gloyn AL. Species-specific differences in the expression of the HNF1A. HNF1B and HNF4A genes. PLoS One. 2009; 4(11):e7855.
  • 39
    Kan AE, Kozlowski K. New distinct lethal osteosclerotic bone dysplasia (Raine syndrome). Am J Med Genet. 1992; 43(5):8604.
  • 40
    Al Mane KA, Coates RK, McDonald P. Intracranial calcification in Raine syndrome. Pediatr Radiol. 1996; 26(1):558.
  • 41
    al-Mane K, al-Dayel F, McDonald P. Intracranial calcification in Raine syndrome: radiological pathological correlation. Pediatr Radiol. 1998; 28(11):8203.
  • 42
    Rejjal A. Raine syndrome. Am J Med Genet. 1998; 78(4):3825.
  • 43
    Shalev SA, Shalev E, Reich D, Borochowitz ZU. Osteosclerosis, hypoplastic nose, and proptosis (Raine syndrome): further delineation. Am J Med Genet. 1999; 86(3):2747.
  • 44
    Rickert CH, Rieder H, Rehder H, Hulskamp G, Hornig-Franz I, Louwen F, Paulus W. Neuropathology of Raine syndrome. Acta Neuropathologica. 2002; 103(3):2817.
  • 45
    Al-Gazali LI, Jehier K, Nazih B, Abtin F, Haas D, Sadagahatian R. Further delineation of Raine syndrome. Clin Dysmorphol. 2003; 12(2):8993.
  • 46
    Hulskamp G, Wieczorek D, Rieder H, Louwen F, Hornig-Franz I, Rickert CH, Horst J, Harms E, Rehder H. Raine syndrome: report of a family with three affected sibs and further delineation of the syndrome. Clin Dysmorphol. 2003; 12(3):15360.
  • 47
    Gunes T, Kurtoglu S, Cetin N, Ozturk MA, Topaloglu N. Raine syndrome associated with cytomegalovirus infection. Turkish J Pediatr. 2005; 47(1):8991.
  • 48
    Chitayat D, Shannon P, Keating S, Toi A, Blaser S, Friedberg T, Superti-Furga A, Chong K, Unger S. Raine syndrome: a rare lethal osteosclerotic bone dysplasia. Prenatal diagnosis autopsy neuropathological findings. Am J Med Genet A. 2007; 143A(24):32805.
  • 49
    Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, de Oliveira JR, Sobrido MJ, Quintans B, Baquero M, Cui X, Zhang XY, Wang L, Xu H, Wang J, Yao J, Dai X, Liu J, Zhang L, Ma H, Gao Y, Ma X, Feng S, Liu M, Wang QK, Forster IC, Zhang X, Liu JY. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet. 2012; 44(3):2546.
  • 50
    Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int. 2009; 85(3):23546.
  • 51
    Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, Fujitab T. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone. 2011; 49(4):9136.
  • 52
    Wang J, Sinha T, Wynshaw-Boris A. Wnt signaling in mammalian development: lessons from mouse genetics. Cold Spring Harb Perspect Biol. 2012; 4(5). DOI:10.1101/cshperspect.a007963
  • 53
    Kouskoura T, Fragou N, Alexiou M, John N, Sommer L, Graf D, Katsaros C, Mitsiadis TA. The genetic basis of craniofacial and dental abnormalities. Schweiz Monatsschr Zahnmed. 2011; 121(7–8):63646.

Supporting Information

  1. Top of page
  2. ABSTRACT
  3. Introduction
  4. Patients and Methods
  5. Results
  6. Discussion
  7. Disclosures
  8. Acknowledgments
  9. References
  10. Supporting Information

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
jbmr1850-0001-sm-SupplFigS1.tif326KSupplementary Figure S1
jbmr1850-0002-sm-SupplMaterial.doc70KSupplementary Material

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.